Clinical Trial Simulation in Drug Development

Brooks, 1995, A simulation study used to design the sequential monitoring plan for a clinical trial, Stat Med, 14, 2227, 10.1002/sim.4780142006 Hale, 1996, Clinical trial simulation as a tool for increased drug development efficiency, Appl Clin Trials, 5, 35 Holford, 2000, Simulation of clinical trials, Annu Rev Pharmacol Toxicol, 40, 209, 10.1146/annurev.pharmtox.40.1.209 Kimko, 2000, Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model, Clin Pharmacol Ther, 68, 568, 10.1067/mcp.2000.110975 Veyrat-Follet, 2000, Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization, Clin Pharmacol Ther, 68, 677, 10.1067/mcp.2000.111948 Chabaud, 2002, Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris, J Pharmacokinet Pharmacodyn, 29, 339, 10.1023/A:1020953107162 Ko, 2002 Bassingthwaighte, 2000, Strategies for the physiome project, Ann Biomed Eng, 28, 1043, 10.1114/1.1313771 Sheiner, 2000, Pharmacokinetic/pharmacodynamic modeling in drug development, Annu Rev Pharmacol Toxicol, 40, 67, 10.1146/annurev.pharmtox.40.1.67 What impact does the use of flight simulators have on commercial aviation? [online]. Available from URL: http://www.airlinesafety.com/faq/faq1.htm.2004 [Accessed 2004 Jul 21]. Jusko, 1994, Physiologic indirect response models characterize diverse types of pharmacodynamic effects, Clin Pharmacol Ther, 56, 406, 10.1038/clpt.1994.155 Charnick, 1995, Perspectives in pharmacokinetics: physiologically based pharmacokinetic modeling as a tool for drug development, J Pharmacokinet Biopharm, 23, 217, 10.1007/BF02354273 Jupp, 1978, Approximation to data by splines with free knots, SIAM J Numer Anal, 15, 328, 10.1137/0715022 Wellstein, 1984, Correlation between pharmacological response, kinetics of plasma concentration and in vitro receptor affinities exemplified with beta-adrenoceptor blocking drugs, Methods Find Exp Clin Pharmacol, 6, 641 Wellstein, 1985, Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man, Eur J Clin Pharmacol, 29, 131, 10.1007/BF00547412 Jusko, 1995, Convergence of direct and indirect pharmacodynamic response models, J Pharmacokinet Biopharm, 23, 5, 10.1007/BF02353781 Kushler, 1991, A model for the identification of hormone pulses, Stat Med, 10, 329, 10.1002/sim.4780100305 Camproux, 1994, Stochastic modeling of the hypothalamic pulse generator activity, Am J Physiol, 267, E795 Hoffman, 1994, The relationship between receptor-effector unit heterogeneity and the shape of the concentration-effect profile: pharmacodynamic implications, J Pharmacokinet Biopharm, 22, 449, 10.1007/BF02353789 Jusko, 1994, Receptor-mediated pharmacodynamics of corticosteroids, Prog Clin Biol Res, 387, 261 Troconiz, 1994, Semiparametric models for antagonistic drug interactions, J Appl Physiol, 76, 2224, 10.1152/jappl.1994.76.5.2224 Holford NH, Hale MD, Ko HC, et al. Simulation in drug development: good practices. Draft Publication of the Center for Drug Development Science (CDDS). Draft version 1.0, 23 Jul, 1999 [online]. Available from URL: http://cdds.georgetown.edu/research/sddgp723.html [Accessed 2004 Jul 19] Greenland, 1987, Interpreting time-related trends in effect estimates, J Chronic Dis, 40, 17S, 10.1016/S0021-9681(87)80005-X US Food and Drug Administration. US Department of Health and Human Services. Innovation or stagnation: challenge and opportunity on the critical path to new medical products [online]. Available from URL: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html [Accessed 2004 Jul 29] Wada, 2001, Combining drug-disease and economic modelling to inform drug development decisions, Drug Discov Today, 6, 1165, 10.1016/S1359-6446(01)02014-1 Kastrissios, 2002, Protocol deviations and execution models Yano, 2001, Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check, J Pharmacokinet Pharmacodyn, 28, 171, 10.1023/A:1011555016423 Duffull, 2000, A pharmacokinetic simulation model for ivabradine in healthy volunteers, Eur J Pharm Sci, 10, 285, 10.1016/S0928-0987(00)00086-5